drugset
drugset / Trial / NCT05492630

Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC73077 in Healthy Subjects

NCT05492630 ↗

Phase 1 Completed 138 enrolled Sunshine Lake Pharma Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The Safety, Tolerability Pharmacokinetic and Food Effect Study of HEC73077 in Healthy Subjects

Timeline

Start
2021-05-24
Primary completion
2023-01-04
Completion
2023-01-04

Drugs

EvaluationDrugModalityDoseRoute
Subject HEC73077 Unknown — —

Indications

diabetic kidney disease